Microbial Pathogens: Helicobacter pylori and Hepatitis Viruses

Helicobacter pylori

Characteristics of Helicobacter pylori

Helicobacter pylori is a Gram-negative, highly motile, spiral-shaped bacterium notable for its multiple polar flagella. It is a significant human pathogen associated with gastrointestinal diseases.

• Gram-negative: Possesses a thin peptidoglycan layer and an outer membrane.

• Motility: Multiple polar flagella enable movement through the viscous mucus lining of the stomach.

• Shape: Spiral morphology aids in colonization of the gastric mucosa.

• Enzyme production: Produces urease, which hydrolyzes urea to ammonia and carbon dioxide, neutralizing stomach acid and facilitating survival.

Example: Urease activity is central to the bacterium's ability to colonize the acidic environment of the stomach.

Clinical Significance

H. pylori is a major cause of peptic ulcers and is implicated as a cofactor in the development of gastric cancer.

• Responsible for approximately 80% of stomach and duodenal ulcers.

• Chronic infection can lead to chronic gastritis and increase the risk of gastric cancers.

• Individuals with type O blood have a 1.5–2 times higher rate of ulcers.

Transmission and Epidemiology

Transmission occurs primarily via person-to-person contact, especially through oral-oral and oral-fecal routes.

• Chronic infections are common unless treated with antibiotics.

• Long-term colonization can persist for years, often asymptomatically.

Diagnosis and Treatment

Diagnosis involves clinical assessment and laboratory testing for the presence of H. pylori or its products.

• Clinical signs: Belching and stomach pain are common symptoms.

• Urease test: A non-invasive diagnostic method where the patient ingests $^{13}C$ or $^{14}C$-labeled urea. Detection of labeled CO2 in exhaled breath indicates urease activity and thus infection.

• Definitive diagnosis: Recovery of organisms from biopsy or stool samples, or detection of antigens.

• Treatment: Usually involves a combination of antibiotics and acid-suppressing drugs.

Example: The Nobel Prize in Physiology or Medicine (2005) was awarded to Robin Warren and Barry Marshall for establishing the link between H. pylori and peptic ulcers.

Hepatitis Viruses

Overview of Hepatitis Viruses

Hepatitis refers to inflammation of the liver, commonly caused by several distinct viruses. These viruses differ in their genetic material, transmission routes, and clinical outcomes.

• DNA virus: Hepatitis B virus (HBV)

• RNA viruses:

  • Hepatitis A virus (HAV): Fecal-oral transmission, least virulent.

  • Hepatitis C virus (HCV): Blood transmission, causes transfusion hepatitis.

  • Hepatitis E virus (HEV): Fecal-oral transmission, similar to HAV.

  • Hepatitis D virus (HDV): Defective RNA virus, only infects cells already infected with HBV.

Hepatitis A Virus (HAV) and Infectious Hepatitis

HAV is an RNA virus transmitted primarily via the fecal-oral route. It does not cause chronic infection and is generally less severe than other hepatitis viruses.

• Reservoirs: Asymptomatic, short-term carriers or individuals with clinical disease.

• Pathogenesis: Multiplies in the small intestine, enters the bloodstream, and is carried to the liver.

• Clinical features: Most infections are subclinical or present with vague, flu-like symptoms; jaundice is rare.

• Treatment: No specific therapy once symptoms begin; supportive care is provided.

• Prevention: Inactivated and attenuated vaccines are available; pooled immune serum globulin may be used for those entering endemic areas.

Hepatitis B Virus (HBV) and Disease

HBV is a DNA virus that multiplies exclusively in the liver, leading to chronic infection and increased risk of liver cancer.

• Transmission: Through breaks in skin or mucous membranes, or by injection into the bloodstream.

• High-risk groups: Homosexuals, drug addicts, and individuals exposed to contaminated blood.

• Pathogenesis: Virus reaches liver cells, multiplies, and releases virions into the blood. Incubation averages 7 weeks.

• Clinical features: Many exhibit few symptoms and develop immunity; others may experience malaise, fever, chills, anorexia, abdominal discomfort, diarrhea, jaundice, rash, and arthritis. Severe cases may progress to chronic liver disease, necrosis, and cirrhosis.

• Dan particle: Refers to the intact virion of HBV.

• Increased risk: Chronic infection increases risk of hepatocellular carcinoma.

Diagnosis and Management of Hepatitis B

Diagnosis is based on risk factor assessment and serological testing for viral antigens and antibodies.

• Serological tests: ELISA for surface antigens.

• Screening: Blood for transfusion, semen for sperm banks, organs for transplant, and routine prenatal testing of pregnant women.

• Treatment: Mild cases managed symptomatically; chronic infections may be treated with interferon.

Prevention of Hepatitis B

Prevention strategies include passive and active immunization.

• Passive immunization: Administration of antibodies to exposed individuals, including neonates born to infected mothers.

• Active immunization: Vaccination recommended for high-risk individuals and all newborns and infants.

Comparison Table: Hepatitis Viruses

Virus	Genome Type	Transmission	Chronicity	Prevention
HAV	RNA	Fecal-oral	No	Vaccine
HBV	DNA	Blood, sexual, perinatal	Yes	Vaccine
HCV	RNA	Blood	Yes	None (as of 2024)
HDV	RNA (defective)	Blood (requires HBV)	Yes	HBV vaccine prevents HDV
HEV	RNA	Fecal-oral	No	Vaccine (limited availability)

Additional info: The notes have been expanded to include definitions, clinical context, and a comparison table for clarity and completeness.